Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B-Reference-Cited by-同舟云学术

Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B

Published:2022-10-25 Issue:2 Volume:39 Page:227-237
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Shah Jinesh¹^ORCID,Kim Hongseok¹^ORCID,Sivamurthy Krupa¹^ORCID,Monahan Paul E.¹^ORCID,Fries Michael¹^ORCID

Affiliation:

1. CSL Behring, King of Prussia, PA, USA

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2022.2133492

Reference40 articles.

1. WFH Guidelines for the Management of Hemophilia, 3rd edition

2. Impact of hemophilia B on quality of life in affected men, women, and caregivers-Assessment of patient-reported outcomes in the B-HERO-S study

3. Hemophilia Gene Therapy: Approaching the First Licensed Product

4. Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B

5. Gene therapy with adeno-associated virus vector 5–human factor IX in adults with hemophilia B

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The evolving landscape of gene therapy for congenital severe hemophilia: a 2024 state of the art;Bleeding, Thrombosis and Vascular Biology;2024-09-04

2. LinQURE: A novel AAV gene silencing platform that supports multi-transcript targeting for complex disorders;Molecular Therapy - Nucleic Acids;2024-09

3. Assessing health plan payer’s budget impact of etranacogene dezaparvovec for the treatment of hemophilia B in the United States;Journal of Managed Care & Specialty Pharmacy;2024-08

4. Analysis of long-term clinical and cost impact of etranacogene dezaparvovec for the treatment of hemophilia B population in the United States;Journal of Medical Economics;2024-06-06

5. Structural characterization of antibody-responses from Zolgensma treatment provides the blueprint for the engineering of an AAV capsid suitable for redosing;2024-05-03